INDEPENDENT COMMUNITY PHARMACY Rx SALES IN 1985 INCREASED 6%
Executive Summary
INDEPENDENT COMMUNITY PHARMACY Rx SALES IN 1985 INCREASED 6% over 1984 sales, according to a preliminary (ITALICS)Lilly Digest(END ITALICS) report previewing data that will appear in the upcoming September publication. Based on a survey of 1,224 independent community pharmacies, Lilly found that pharmacies' Rx sales, on average, increased from $345,435 in 1984 to $366,903 in 1985. New Rxs as a percentage of all Rxs rose to 49.5% compared with 48.6% in 1984, while new Rxs dispensed fell slightly (0.4%) to 13,919. Renewed Rxs dispensed dropped 4.3% to 14,198. The gain in Rx revenue, however, was achieved by an 8.8% increase in the cost of the average Rx (from $12 in 1984 to $13.05 in 1985). While Rx sales increased, sales of other goods declined 1.6% -- from $225,879 in 1984 to $222,439 in 1985. Rx sales comprised 62.3% of total pharmacy sales in 1985, compared with 60.5% in the previous year, according to the Lilly data. The decline in non-Rx sales offset the Rx gain, lowering the total sales increase to 3.2% ($589,342 in 1985 compared with $571,313 in 1984). The (ITALICS)Digest(END ITALICS) report notes that the growth in overall sales "is lower than the average annual growth rate of 9% observed over the decade." The 3% increase in sales revenue also falls below the average growth rate of the last five years which "appears to have stabilized in the range of 5-to-6%," the report observes. The value of Rx inventory at cost increased 6.6%, from $36,343 to $38,753. However, it remained fairly constant as a percentage of Rx sales (10.6% in 1985 compared with 10.5% in 1984). The cost of other inventory declined 1% to $48,625, and also remained relatively stable as a percentage of sales (21.9% in 1985 v. 21.7% in 1984). Combined, the cost of all inventory as a percentage of total sales increased 2.3% to $87,378. Annual inventory turnover rate dropped from 4.6 times to 4.5 times.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth